109
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): Part II. Albumin-bound carbamazepine nanoparticles (ABCns)

, &
Pages 524-534 | Received 02 Apr 2016, Accepted 02 Aug 2016, Published online: 22 Aug 2016
 

Abstract

Carbamazepine (CBZ) is a BCS Class II drug with poor solubility profile. In order to improve the physicochemical properties of CBZ, albumin (HSA)-bound CBZ nanoparticles (ABCns) were prepared. Drug-loading studies indicated that monomeric ABCns can be fabricated by self-assembly of anhydrous form III of CBZ and HSA in molar ratios of 1:1 or 2:1 within 0.5 h in phosphate buffer pH 7.4 with particle size in the range of 10–20 nm. Approximately 73–76% of the CBZ was encapsulated within HSA and 20–40% CBZ was released from the ABCns over 8 days. In conclusion, novel ABCns can be fabricated with sustained-release of CBZ for over 8 days which can significantly improve the physicochemical profile of CBZ.

View correction statement:
Correction to: Erukula and Chatterjee, Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): Part II. Albumin-bound carbamazepine nanoparticles (ABCns)

Acknowledgements

The authors would like to thank Vladimir Poltoratsky, PhD for providing A549 cells.

Disclosure statement

The authors report no conflict of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.